AXS Stock Analysis: AXIS Capital Holdings | NYSE
Insurance - Specialty | NYSE, USA | Market Cap: 7.275m USD | 12M Return: 12.9% | BMG0692U1099 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 67.3M
EPS Trend: 95.7%
Qual. Beats: -1
Rev. Trend: 98.8%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AXIS Capital Holdings Limited is a Bermuda-based specialty insurance and reinsurance provider operating through two main segments: Insurance and Reinsurance. The Insurance segment offers a diverse range of specialty coverages, including professional liability (such as directors and officers, errors and omissions, and medical malpractice), property, marine and aviation, personal accident and travel, specialty health, pet insurance, and cyber and political risk products. The Reinsurance segment provides treaty and facultative reinsurance across lines including agriculture, catastrophe, accident and health, credit and surety, motor, professional, property, and liability. The company serves commercial enterprises, financial institutions, and other professional clients across Bermuda, the United States, and international markets.
Founded in 2001 and headquartered in Pembroke, Bermuda, AXS is listed on the NYSE and operates within the Property & Casualty Insurance sub-industry. Bermuda is a globally significant hub for the insurance and reinsurance industry due to its specialized regulatory framework and proximity to major risk exposures, particularly in catastrophe-prone regions like the U.S. coastline. Unlike standard personal lines insurers, specialty insurers like AXS focus on complex, higher-severity risks that require tailored underwriting expertise.
- Reinsurance pricing hardens following elevated catastrophe losses
- Specialty insurance renewal rates continue upward momentum
- Higher investment yields boost net income and book value
- Capital return program expands through buybacks and dividends
| Net Income: 1.23b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.34 > 1.0 |
| NWC/Revenue: -109.4% < 20% (prev 232.0%; Δ -341.4% < -1%) |
| CFO/TA 0.06 > 3% & CFO 2.30b > Net Income 1.23b |
| Net Debt (-4.49b) to EBITDA (1.49b): -3.01 < 3 |
| Current Ratio: 0.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (74.2m) vs 12m ago -6.46% < -2% |
| Gross Margin: 44.51% > 18% (prev 28.95%; Δ 15.56% > 0.5%) |
| Asset Turnover: 19.28% > 50% (prev 17.90%; Δ 1.39% > 0%) |
| Interest Coverage Ratio: 20.71 > 6 (EBIT TTM 1.38b / Interest Expense TTM 66.8m) |
| A: -0.20 (Total Current Assets 1.35b - Total Current Liabilities 8.81b) / Total Assets 36.6b |
| B: 0.24 (Retained Earnings 8.61b / Total Assets 36.6b) |
| C: 0.04 (EBIT TTM 1.38b / Avg Total Assets 35.4b) |
| D: 0.22 (Book Value of Equity 6.50b / Total Liabilities 30.1b) |
| Altman-Z'' = -0.08 = B |
| DSRI: 0.88 (Receivables 13.6b/13.9b, Revenue 6.82b/6.11b) |
| GMI: 0.65 (GM 28.95% / 44.51%) |
| AQI: 2.80 (AQ_t 0.96 / AQ_t-1 0.34) |
| SGI: 1.12 (Revenue 6.82b / 6.11b) |
| TATA: -0.03 (NI 1.23b - CFO 2.30b) / TA 36.6b) |
| Beneish M = -2.30 (Cap -4..+1) = BBB |
As of October 25, 2026, the stock is trading at USD 102.63 with a total of 745,303 shares traded. Over the past week, the price has changed by +3.01%, over one month by +8.18%, over three months by -10.05% and over the past year by +12.88%.
Current recommended Stop Loss: 99.90 (which is 2.7% or 1.4 ATR below the current price).
AXIS Capital Holdings has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy AXS.
- StrongBuy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 119.6 | 16.5% |
P/E Trailing = 7.0867
P/E Forward = 7.2939
P/S = 1.0691
P/B = 1.1801
P/EG = 1.1787
Revenue TTM = 6.82b USD
EBIT TTM = 1.38b USD
EBITDA TTM = 1.49b USD
Long Term Debt = 1.38b USD (from longTermDebt, last quarter)
Short Term Debt = 108.3m USD (from shortTermDebt, last quarter)
Debt = 1.60b USD (from shortLongTermDebtTotal, last quarter) + Leases 108.3m
Net Debt = -4.49b USD (calculated: Debt 1.60b - CCE 6.09b)
Enterprise Value = 2.79b USD (7.28b + Debt 1.60b - CCE 6.09b)
Interest Coverage Ratio = 20.71 (Ebit TTM 1.38b / Interest Expense TTM 66.8m)
EV/FCF = 2.41x (Enterprise Value 2.79b / FCF TTM 1.16b)
FCF Yield = 41.54% (FCF TTM 1.16b / Enterprise Value 2.79b)
FCF Margin = 16.95% (FCF TTM 1.16b / Revenue TTM 6.82b)
Net Margin = 18.02% (Net Income TTM 1.23b / Revenue TTM 6.82b)
Gross Margin = 44.51% ((Revenue TTM 6.82b - Cost of Revenue TTM 3.79b) / Revenue TTM)
Gross Margin QoQ = 46.77% (prev 47.23%)
Tobins Q-Ratio = 0.08 (Enterprise Value 2.79b / Total Assets 36.6b)
Interest Expense / Debt = 4.19% (Interest Expense 66.8m / Debt 1.60b)
Taxrate = 8.27% (110.6m / 1.34b)
NOPAT = 1.27b (EBIT 1.38b * (1 - 8.27%))
Current Ratio = 0.12 (Total Current Assets 1.35b / Total Current Liabilities 11.2b)
Debt / Equity = 0.25 (Debt 1.60b / totalStockholderEquity, last quarter 6.50b)
Debt / EBITDA = -3.01 (Net Debt -4.49b / EBITDA 1.49b)
Debt / FCF = -3.88 (Net Debt -4.49b / FCF TTM 1.16b)
Total Stockholder Equity = 6.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.47% (Net Income 1.23b / Total Assets 36.6b)
RoE = 19.21% (Net Income TTM 1.23b / Total Stockholder Equity 6.40b)
RoCE = 17.77% (EBIT 1.38b / Capital Employed (Equity 6.40b + L.T.Debt 1.38b))
RoIC = 3.50% (NOPAT 1.27b / Invested Capital 36.3b)
WACC = 5.28% (E(7.28b)/V(8.87b) * Re(5.59%) + D(1.60b)/V(8.87b) * Rd(4.19%) * (1-Tc(0.08)))
Discount Rate = 5.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.08 | Cagr: -6.20%
[DCF] Terminal Value 77.97% ; FCFF base≈1.08b ; Y1≈1.24b ; Y5≈1.82b
[DCF] Fair Price = 437.3 (EV 27.4b - Net Debt -4.49b = Equity 31.9b / Shares 73.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.72 | EPS CAGR: 13.97% | SUE: -2.14 | # QB: -1
Revenue Correlation: 98.78 | Revenue CAGR: 7.51% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-09-30): EPS=2.85 | Chg30d=+1.57% | Revisions=+12% | Analysts=11
EPS current Year (2026-12-31): EPS=12.25 | Chg30d=-0.28% | Revisions=-12% | GrowthEPS=-5.2% | GrowthRev=+2.6%
EPS next Year (2027-12-31): EPS=13.37 | Chg30d=-1.14% | Revisions=-67% | GrowthEPS=+9.2% | GrowthRev=+6.9%
[Analyst] Revisions Ratio: -32% (up=5, down=11)